Bruker Corporation (BRKR) — Analysis Summary
Bruker Corporation (BRKR) has a market cap of $8.98B with year-over-year revenue growth of +2.1%. Net margin stands at -0.3%. The stock trades at a P/E ratio of -773.9.
Key Takeaways
- Revenue changed +2.1% year-over-year
- Net margin of -0.3%
- P/E ratio of -773.9
Compared to other companies in the LABORATORY ANALYTICAL INSTRUMENTS sector, BRKR posted revenue growth of +2.1% and trades at a P/E of -773.9.
Bruker Corporation (BRKR)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 6.1x — highly leveraged, potential refinancing risk
Interest coverage at 0.8x — earnings do not cover interest payments
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Employees
11,085
Headquarters
BILLERICA, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.20
Dividend Yield
0.33%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.